17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
PHASE1CompletedINTERVENTIONAL
Timeline
Start Date
October 31, 2004
Study Completion Date
October 31, 2006
Conditions
Leukemia
Interventions
DRUG
tanespimycin
Trial Locations (1)
90095
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Jonsson Comprehensive Cancer Center
OTHER
NCT00100997 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | Biotech Hunter | Biotech Hunter